As anti-MAG neuropathy is the most common disabling paraproteinemic neuropathy and since the anti-MAG antibodies appear to exert a direct pathogenic effect on the myelin structure and function, B cells depleting therapies have been the main therapeutic mode of treatment. This evidence concerns the gene MAG and neuropathy.